Sugi Predict

Sugi Predict / Compounds / SCHEMBL845813

SCHEMBL845813

SCHEMBL845813

c1cc(-c2ncc3cc[nH]c3n2)c[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 6/20 0.37
▸ AXL P30530 2/20 0.37
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ NUDT1 P36639 2/20 0.35
▸ RIPK1 Q13546 3/20 0.35
▸ PPARA Q07869 1/20 0.34
▸ MAPK1 P28482 5/20 0.33
▸ CDK7 P50613 2/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CCNC P24863 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ CCNH P51946 1/20 0.33
▸ MNAT1 P51948 1/20 0.33
▸ CDK6 Q00534 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352947 0.79 CDK8 (0.54) CDK8AXLALOX5APFEN1NUDT1
SCHEMBL844875 0.78 MAPK1 (0.53) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL20508757 0.77 PIK3CD (0.56) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL793847 0.77 PPARA (0.33) PPARAMAPK1
SCHEMBL5607323 0.76 RIPK1 (0.57) CDK8AXLALOX5APFEN1RIPK1
SCHEMBL28322681 0.76 ADORA3 (0.40) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL17065188 0.76 MAPK1 (0.51) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL20162798 0.72 FEN1 (0.41) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL4283965 0.70 AXL (0.36) CDK8AXLPIK3CDPIK3CAPIK3CB
SCHEMBL4280303 0.70 AXL (0.40) CDK8AXLPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220372135-A1 METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS DISC MEDICINE, INC. (US) 2022-11-24 — — US disclosed
WO-2021062163-A1 METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS DISC MEDICINE, INC. (US) 2021-04-01 — — WO disclosed
WO-2021062171-A1 METHODS FOR TREATING ANEMIA OF CHRONIC DISEASE DISC MEDICINE, INC. (US) 2021-04-01 — — WO disclosed
US-10640506-B2 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2020-05-05 — — US disclosed
EP-3600440-A1 REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS Sienna Biopharmaceuticals, Inc. (US) 2020-02-05 — — EP disclosed
WO-2020023389-A1 REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS SIENNA BIOPHARMACEUTICALS, INC. (US) 2020-01-30 — — WO disclosed
US-20190135813-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2019-05-09 — — US disclosed
WO-2018175315-A1 POLYMER CONJUGATES OF STAUROSPORINE DERIVATIVES HAVING REDUCED EXPOSURE SIENNA BIOPHARMACEUTICALS, INC. (US) 2018-09-27 — — WO disclosed
WO-2018175340-A1 REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS SIENNA BIOPHARMACEUTICALS, INC. (US) 2018-09-27 — — WO disclosed
US-9334274-B2 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2016-05-10 — — US disclosed
EP-2432555-B1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORP (US) 2014-04-30 — — EP disclosed
EP-2640723-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS Incyte Corporation (US) 2013-09-25 — — EP disclosed
US-20120149681-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2012-06-14 — — US disclosed
WO-2012068450-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION (US) 2012-05-24 — — WO disclosed
CN-102458581-A N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d ] pyrimidines and pyrrol-3-yl-pyrrolo [2,3-d ] pyrimidines as JANUS kinase inhibitors INCYTE CORP 2012-05-16 — — CN disclosed
EP-2432555-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS Incyte Corporation (US) 2012-03-28 — — EP disclosed
WO-2011028685-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2011-03-10 — — WO disclosed
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2011-03-10 — — US disclosed
WO-2010135650-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2010-11-25 — — WO disclosed
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION 2010-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298334-A1 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 CDK8 237/4885AXL 449/4885PIK3CD 89/4885
US-20110059951-A1 HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS JAK3, JAK1, JAK2 CDK8 46/4885AXL 296/4885PIK3CD 48/4885
US-10640506-B2 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors JAK2, JAK1, JAK3 CDK8 409/4885AXL 975/4885PIK3CD 111/4885
US-20120149681-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 CDK8 319/4885AXL 781/4885PIK3CD 144/4885
US-20190135813-A1 CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS JAK2, JAK1, JAK3 CDK8 409/4885AXL 975/4885PIK3CD 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.